Program
amivantamab
Also written as “Amivantamab”, “Amivantamab IV” and “Amivantamab SC”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Squamous Cell Carcinoma of Head and Neck · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 2 companies.
Drug pageAmivantamab: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 1512 open or running | phase 3since Jul 23, 2020 | Nov 18, 2015 | Dec 31, 2026phase 1 · NCT02609776 |
| AstraZenecaits history only | 11 open or running | phase 2since Mar 24, 2023 | Mar 24, 2023 | Oct 1, 2027phase 2 · NCT05801029 |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 18, 2015.
- Jun 9, 2019Named amivantamabINNProposed as its International Nonproprietary Name in WHO's List 121
- Aug 30, 2019Phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463 · 701 enrolled · United States, China, France and more
- Jul 23, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04487080 · 1,074 enrolled · United States, Argentina, Australia and more
- Jun 23, 2021Phase 2 study in Stomach NeoplasmsNCT04945733 · 62 enrolled · Japan
- Jul 30, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04988295 · 776 enrolled · United States, Argentina, Belgium and more
- May 17, 2022Phase 2 study in Colorectal NeoplasmsNCT05379595 · 225 planned · United States, Belgium, Canada and more
- May 19, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05388669 · 418 enrolled · United States, Argentina, Australia and more
- Aug 3, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05488314 · 57 enrolled · United States, Brazil, Canada and more
- Dec 8, 2022Phase 2 study in Carcinoma, HepatocellularNCT05653427 · 18 enrolled · China
- Nov 2, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06120140 · 305 enrolled · United States, Argentina, Brazil and more
- Apr 23, 2024Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06385080 · 287 planned · United States, China, France and more
- Jul 29, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06532032 · 12 enrolled · United States, Taiwan, Turkey (Türkiye) and more
- Oct 28, 2024Phase 3 study in Colorectal NeoplasmsNCT06662786 · 1,000 planned · United States, Belgium, Brazil and more
- Dec 20, 2024Phase 3 study in Colorectal NeoplasmsNCT06750094 · 700 planned · United States, Australia, Belgium and more
- Dec 1, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT07276399 · 600 planned · United States, Australia, Austria and more
Ahead
- Dec 31, 2026Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT02609776
- Feb 12, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT04077463
- Apr 27, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT05379595
- Apr 28, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05488314
TargetBeta
“A human bispecific antibody targeting both epidermal growth factor receptor EGFR and hepatocyte growth factor receptor (HGFR; cMet), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Hepatocyte growth factor receptor inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 15 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07276399Squamous Cell Carcinoma of Head and Neck · United States, Australia, Austria and more | 3 | Recruiting | Jun 18, 2029 | 600 |
| NCT06750094Colorectal Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | Dec 15, 2027 | 700 |
| NCT06662786Colorectal Neoplasms · United States, Belgium, Brazil and more | 3 | Recruiting | Dec 15, 2028 | 1,000 |
| NCT06532032Carcinoma, Non-Small-Cell Lung · United States, Taiwan, Turkey (Türkiye) and more | 2 | Completed | May 14, 2026 | 12 |
| NCT06385080Squamous Cell Carcinoma of Head and Neck · United States, China, France and more | 2 | Recruiting | Dec 27, 2032 | 287 |
| NCT06120140Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 2 | Active, not recruiting | May 31, 2027 | 305 |
| NCT05653427Carcinoma, Hepatocellular · China | 2 | Terminated | Oct 10, 2023 | 18 |
| NCT05488314Carcinoma, Non-Small-Cell Lung · United States, Brazil, Canada and more | 2 | Active, not recruiting | Apr 28, 2027 | 57 |
| NCT05388669Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 3, 2024 | 418 |
| NCT05379595Colorectal Neoplasms · United States, Belgium, Canada and more | 2 | Recruiting | Apr 27, 2027 | 225 |
| NCT04988295Carcinoma, Non-Small-Cell Lung · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jul 10, 2023 | 776 |
| NCT04945733Stomach Neoplasms · Japan | 2 | Terminated | Jul 3, 2023 | 62 |
| NCT04487080Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 11, 2023 | 1,074 |
| NCT04077463Carcinoma, Non-Small-Cell Lung · United States, China, France and more | 1 | Active, not recruiting | Feb 12, 2027 | 701 |
| NCT02609776Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 1 | Active, not recruiting | Dec 31, 2026 | 751 |
How it is read
Names in the registry
- “Amivantamab”, 15 entries
- “Amivantamab IV”, 2 entries
- “Amivantamab SC”, 1 entry
- “Amivantamab Intravenous”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 9 studies
- Colorectal Neoplasms, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 2 studies
- Carcinoma, Hepatocellular, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.